A pill Rozuvastatin-Darnitsa is taken at the following indications:

• Treatment of a hypercholesterolemia.
• Prevention of cardiovascular disturbances.

Structure

active ingredient: rosuvastatin;

1 tablet contains rosuvastatin 10 mg in the form of rosuvastatin of calcium of 10.40 mg of rosuvastatin of 20 mg in the form of rosuvastatin of calcium of 20.80 mg;

excipients: lactose, cellulose microcrystalline, calcium hydrophosphate, krospovidon, povidone, magnesium stearate, opadray II 85F pink.

Contraindication

• Hypersensitivity to rosuvastatin or to other components of medicine;
• a disease of a liver in an active phase among which there is a steady increase in serumal transaminases of an unknown etiology and any increase in transaminases in blood serum by 3 times exceeds the upper bound of norm;
• heavy renal failures (clearance of creatinine <30 ml/min.);
• myopathy;
• simultaneous use with cyclosporine;
• period of pregnancy and feeding by a breast. Medicine is contraindicated to women of reproductive age, not using appropriate contraceptives.

Dose of 40 mg is contraindicated to patients with tendency to a myopathy/rhabdomyolysis. Can treat risk factors:

• moderately severe renal failure (clearance of creatinine <60 ml/min.);
• hypothyroidism;
• existence in the individual or family anamnesis of hereditary muscular diseases;
• existence in the anamnesis of the miotoksichnost caused by use of other inhibitors of GMG-KoA-reduktazy or a fibratama;
• alcohol abuse;
• a situation which can lead to increase in concentration of rosuvastatin in blood plasma;
• accessory of patients to Mongoloid races;
• simultaneous use of fibrat.

Route of administration

Before an initiation of treatment a standard holesterinosnizhayushchy diet which needs to be observed also during treatment. The dose should be selected individually depending on the purpose of therapy and the response of the patient to treatment, in view of the current recommendations.

Medicine can be accepted at any time, irrespective of meal.

Pregnant

Medicine is contraindicated to

Feature of use

Prescription of medicine to children only the expert has to carry out

.

to Apply

to children and teenagers aged from 10 up to 17 years (boys at a stage of development there is II and above Tanner and girls in whom periods began less than a year ago).

Drivers

At control of motor transport or other mechanisms should consider an opportunity dizziness the treatment period rosuvastatin.

Overdose

Specific treatment of overdose. Symptomatic treatment, maintenance therapy is recommended. It is necessary to control functions of a liver and the KFK level. The efficiency of a hemodialysis is improbable.

Side reactions

from nervous system: often: headache, dizziness;

from digestive tract: often constipation, nausea, abdominal pain;

from an endocrine system: often diabetes (frequency depends on presence of risk factors: glucose level on an empty stomach ≥ 5.6 mmol/l, BMI> 30 kg/sq.m, the increased levels of triglycerides, arterial hypertension in the anamnesis).

Interaction

Digoksin. According to researches on interaction, clinically significant interaction is not expected.

Fusidic acid. The research of interaction of rosuvastatin with fusidic acid was not conducted. Risk of a myopathy, including. with a rhabdomyolysis, fusidic acid with statines can be increased as a result of the accompanying use system. The mechanism of this interaction (pharmakodinamichesky or pharmacokinetic, or both) is not found out yet. It was reported about rhabdomyolysis cases (including with a lethal outcome) at the patients receiving this combination. If system use fusidic acid is necessary, rosuvastatin it is desirable to stop treatment during all term of treatment fusidic acid.

to Store

in original packing at a temperature not above 25 °C.

to Store

out of children's reach.

Expiration date. 3 years.